• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内分泌外科的转化研究。

Translational research in endocrine surgery.

作者信息

Sherman Scott K, Howe James R

机构信息

Department of Surgery, Carver College of Medicine, The University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.

出版信息

Surg Oncol Clin N Am. 2013 Oct;22(4):857-84. doi: 10.1016/j.soc.2013.06.012. Epub 2013 Jul 26.

DOI:10.1016/j.soc.2013.06.012
PMID:24012403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3794713/
Abstract

This article reviews translational research in endocrine surgery, with a focus on disorders of the thyroid, parathyroids, adrenals, and endocrine pancreas. Discovery of genes responsible for heritable endocrine cancer syndromes has increased knowledge of the causes and mechanisms of endocrine cancer and has refined surgical treatment options. Knowledge of mutations in sporadic cancer has led to rapid progress in small-molecule kinase inhibitor strategies. These breakthroughs and their influence on current therapy are discussed to provide surgeons with an overview of the basic science research currently creating new clinical treatments and improving patient care.

摘要

本文回顾了内分泌外科的转化研究,重点关注甲状腺、甲状旁腺、肾上腺和内分泌胰腺的疾病。对遗传性内分泌癌综合征相关基因的发现,增加了我们对内分泌癌病因和机制的了解,并优化了手术治疗方案。对散发性癌症中突变的认识,推动了小分子激酶抑制剂策略的快速发展。本文将讨论这些突破及其对当前治疗的影响,以便为外科医生提供基础科学研究的概述,这些研究目前正在创造新的临床治疗方法并改善患者护理。

相似文献

1
Translational research in endocrine surgery.内分泌外科的转化研究。
Surg Oncol Clin N Am. 2013 Oct;22(4):857-84. doi: 10.1016/j.soc.2013.06.012. Epub 2013 Jul 26.
2
[Current operative techniques and strategies in endocrine surgery].[内分泌外科的当前手术技术与策略]
Ther Umsch. 2011 Jun;68(6):279-83. doi: 10.1024/0040-5930/a000165.
3
What's new in general surgery: endocrine surgery.普通外科的新进展:内分泌外科
J Am Coll Surg. 2002 Sep;195(3):364-71. doi: 10.1016/s1072-7515(02)01307-8.
4
Endocrine surgery.内分泌外科
Surg Clin North Am. 2014 Jun;94(3):xv-xvi. doi: 10.1016/j.suc.2014.04.001.
5
Presidential address: a new face for endocrine surgery.主席致辞:内分泌外科的新面貌
Surgery. 2013 Dec;154(6):1143-5. doi: 10.1016/j.surg.2013.05.041.
6
Endocrine surgery--a 23-hour specialty?内分泌外科——一门需要23小时投入的专业?
ANZ J Surg. 2009 May;79(5):320-2. doi: 10.1111/j.1445-2197.2009.04460.x.
7
Continued Progress and Advancements in Endocrine Surgery.内分泌外科的持续进展与进步
Surg Clin North Am. 2024 Aug;104(4):xv-xvi. doi: 10.1016/j.suc.2024.02.018. Epub 2024 Mar 12.
8
Endocrine surgery: current and future issues.内分泌外科:当前与未来的问题
Int J Surg. 2014;12 Suppl 1:S1-2. doi: 10.1016/j.ijsu.2014.05.075. Epub 2014 May 29.
9
[Endocrinologic surgery in change].[不断变革中的内分泌外科]
Tidsskr Nor Laegeforen. 2007 May 3;127(9):1174.
10
Endocrine surgery.内分泌外科
J Am Coll Surg. 2000 Feb;190(2):129-33. doi: 10.1016/s1072-7515(99)00247-1.

引用本文的文献

1
Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.新型胰腺神经内分泌肿瘤转移发光小鼠模型的建立与比较。
Sci Rep. 2021 May 13;11(1):10252. doi: 10.1038/s41598-021-89866-1.
2
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.里程碑系列:小肠神经内分泌肿瘤的管理
Ann Surg Oncol. 2021 May;28(5):2741-2751. doi: 10.1245/s10434-020-09566-4. Epub 2021 Jan 15.
3
Small Bowel Neuroendocrine Tumors.小肠神经内分泌肿瘤
Curr Probl Surg. 2020 Dec;57(12):100823. doi: 10.1016/j.cpsurg.2020.100823. Epub 2020 May 15.
4
Surgical Management of Neuroendocrine Tumor Liver Metastases.神经内分泌肿瘤肝转移的外科治疗。
Surg Oncol Clin N Am. 2021 Jan;30(1):39-55. doi: 10.1016/j.soc.2020.08.001. Epub 2020 Oct 20.
5
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.RABL6A 通过抑制抑瘤性的 PP2A/AKT 信号通路促进胰腺神经内分泌肿瘤的生长。
J Clin Invest. 2019 Mar 4;129(4):1641-1653. doi: 10.1172/JCI123049.
6
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.胰腺神经内分泌肿瘤的转化诊断与治疗
Clin Cancer Res. 2016 Oct 15;22(20):5022-5029. doi: 10.1158/1078-0432.CCR-16-0435.
7
RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.RABL6A以Rb1依赖的方式促进G1-S期进程和胰腺神经内分泌肿瘤细胞增殖。
Cancer Res. 2014 Nov 15;74(22):6661-70. doi: 10.1158/0008-5472.CAN-13-3742. Epub 2014 Oct 1.
8
Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.基因表达能准确区分小肠和胰腺神经内分泌肿瘤的肝转移灶。
Clin Exp Metastasis. 2014 Dec;31(8):935-44. doi: 10.1007/s10585-014-9681-2. Epub 2014 Sep 21.
9
Medical management of metastatic medullary thyroid cancer.转移性甲状腺髓样癌的医学治疗。
Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18.
10
GIPR expression in gastric and duodenal neuroendocrine tumors.胃和十二指肠神经内分泌肿瘤中的 GIPR 表达。
J Surg Res. 2014 Aug;190(2):587-93. doi: 10.1016/j.jss.2014.01.044. Epub 2014 Jan 29.

本文引用的文献

1
Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.胃抑制多肽受体(GIPR)是神经内分泌肿瘤成像和治疗的一个有前途的靶点。
Surgery. 2013 Dec;154(6):1206-13; discussion 1214. doi: 10.1016/j.surg.2013.04.052.
2
Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.胃肠道神经内分泌肿瘤原发灶和转移灶中膜蛋白的过度表达。
Ann Surg Oncol. 2013 Dec;20 Suppl 3(0 3):S739-S746. doi: 10.1245/s10434-013-3318-6. Epub 2013 Oct 10.
3
New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers.甲状腺结节癌症诊断的新策略:分子标志物的影响。
Clin Cancer Res. 2013 May 1;19(9):2283-8. doi: 10.1158/1078-0432.CCR-12-1253. Epub 2013 Feb 19.
4
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.ATP1A1 和 ATP2B3 中的体细胞突变导致醛固酮瘤和继发性高血压。
Nat Genet. 2013 Apr;45(4):440-4, 444e1-2. doi: 10.1038/ng.2550. Epub 2013 Feb 17.
5
BRAF V600E inhibition in anaplastic thyroid cancer.BRAF V600E 抑制在间变性甲状腺癌中的作用
N Engl J Med. 2013 Feb 14;368(7):684-5. doi: 10.1056/NEJMc1215697.
6
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.索拉非尼增强晚期甲状腺癌的放射性碘摄取。
N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.
7
The genetics of neuroendocrine tumors.神经内分泌肿瘤的遗传学。
Semin Oncol. 2013 Feb;40(1):37-44. doi: 10.1053/j.seminoncol.2012.11.005.
8
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.国际原子能机构、欧洲核医学协会和核医学分子影像学会联合发布的神经内分泌肿瘤肽受体放射性核素治疗实践指南。
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
9
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.荷兰基于组织学分级的神经内分泌肿瘤发病率和生存率:癌症登记 20 年经验。
Eur J Cancer. 2013 May;49(8):1975-83. doi: 10.1016/j.ejca.2012.12.022. Epub 2013 Jan 23.
10
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.表皮生长因子受体抑制剂耐药的非小细胞肺癌治疗中 PI3K/Akt/mTOR 通路抑制剂的临床前原理。
Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16.